New treatment options for kids with treatment-resistant medulloblastoma

Medulloblastoma is a type of malignant brain tumor that is typically diagnosed in children and adolescents. It is one of the most common brain tumors seen in kids and accounts for 15-20% of all pediatric brain tumors. Medulloblastoma tumors usually form in the cerebellum. The cerebellum is the part of the brain that controls balance,…


The search for effective treatment for kids with atypical teratoid rhabdoid tumor (ATRT)

Atypical teratoid/rhabdoid tumor (ATRT) is a rare and highly aggressive pediatric brain tumor. It typically affects kids 3 years and younger. The 5-year overall survival rate for kids with ATRT is about 30%. The standard treatment for ATRT is chemotherapy and radiation, which can improve outcomes, but leaves kids with significant long-term side effects. The…


Developing and improving models for testing new treatments for kids with cancer

Brain and spine tumors are one of the most common forms of cancer found in kids, second only to leukemia. Despite significant advances in treatment, brain tumors remain the leading cause of cancer-related death in children. The kids who do survive often suffer from long-term side effects from treatment, and face the risk of recurrence…


2022 Research Funded

Thanks to the support of generous donors, 28 projects have received funding for 2022. These projects address the widest range of pediatric cancers and represent the largest single-year financial support in the history of The Morgan Adams Foundation. This groundbreaking research has the potential to change the landscape for kids with cancer. The projects are…


Five new clinical trials for kids with cancer

Progress in medical research takes time – and requires sustained funding. Support for kids’ cancer research is critically important. Donations from caring individuals make possible studies into safer and more effective treatments for kids and teens. Without donor generosity, the good ideas doctors and researchers have would never make it out of the lab and into…


Newsletter Fall 2017 Page 4